focus -WSS

focus

author：entertainment 2025-10-04 04:01:02 - browse：829

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： European officials brace for rough respiratory virus season

knowledge

WSS

New oral drug delivery patch is modeled after octopus tentacles

The United States is paying nearly triple for new Covid vaccines

Health and fitness trackers are measuring the wrong things

The stability of $0 premiums in Medicare Advantage

The stability of $0 premiums in Medicare Advantage

Heart disease and mental health: A look at cardiac psychology

entertainment

focus

Wikipedia

Peter Hotez and the public health issue of online harassment

Experts study whether long Covid risk adds up with each reinfection

Duchenne breakthrough therapy leaves behind pioneering families

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

New England Journal of Medicine addresses racist history, slavery

As demand for Covid shots wanes, Moderna seeks its next success

New England Journal of Medicine addresses racist history, slavery

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Wikipedia

Nobel honors Karikó and Weissman's enduring partnership

Experts study whether long Covid risk adds up with each reinfection

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

HHS names first

Medicare innovation center doesn’t save money, experts say

Nobel honors Karikó and Weissman's enduring partnership

knowledge

knowledge

knowledge

hotspot